Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration by Miller, A-M et al.
1 
 
Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for 
neurodegeneration  
 
 
Authors: Miller A-M, Rutkowska A, Bahl JM, Herukka S-K, Koel-Simmelink MJA, Kruse N, 
Mollenhauer B, Siloaho M, Skinningsrud A, ZETTERBERG H, Teunissen CE, Lawlor BA 
 
Key words: biomarker, validation, neurofilament light (NfL), cerebrospinal fluid (CSF), multi-centre 
 
 
 
Corresponding Author:  
Anne-Marie Miller 
Mercer’s Institute for Research on Aging 
St. James’s Hospital 
Dublin 8 
Ireland. 
Ph: 00 353 1 4284531 
Email: milleram@tcd.ie 
 
 
 
 
2 
 
 
Contents 
Introduction ............................................................................................................................................. 4 
Methods .................................................................................................................................................. 5 
Study design ........................................................................................................................................ 5 
ELISA ................................................................................................................................................. 5 
Sensitivity ........................................................................................................................................... 6 
Precision .............................................................................................................................................. 6 
Recovery ............................................................................................................................................. 6 
Linearity of dilution ............................................................................................................................ 6 
Parallelism........................................................................................................................................... 7 
Inter-laboratory accuracy samples ...................................................................................................... 7 
Data analysis ....................................................................................................................................... 7 
Results ..................................................................................................................................................... 8 
Sensitivity ........................................................................................................................................... 8 
Precision .............................................................................................................................................. 8 
Recovery (selectivity) ......................................................................................................................... 8 
Linearity of dilution ............................................................................................................................ 8 
Parallelism........................................................................................................................................... 8 
Inter-laboratory precision .................................................................................................................... 8 
Discussion ............................................................................................................................................. 10 
Recovery (selectivity) ....................................................................................................................... 10 
Linearity of dilution .......................................................................................................................... 10 
Parallelism......................................................................................................................................... 11 
Inter-laboratory precision .................................................................................................................. 11 
Limitations and recommendations .................................................................................................... 12 
Acknowledgements ............................................................................................................................... 12 
References ............................................................................................................................................. 13 
Figures .................................................................................................................................................. 16 
 
3 
 
 
Abstract 
Neurofilament light (NfL), a putative cerebrospinal fluid (CSF) biomarker, has proven capacity to 
support the diagnosis of, or differentiate between, various sub-types of neurodegenerative disorders. It 
also functions as a marker of disease severity and prognosis with potential to contribute to patient 
stratification in clinical and scientific research. Here, a commercially available NfL enzyme-linked 
immunosorbent assay (ELISA) (UmanDiagnostics, Umeå, Sweden) was validated in a multi-centred 
setting using standardised operating procedures (SOPs) devised as part of the Joint Program for 
Neurodegenerative Diseases (JPND) BIOMARKAPD project. Validation parameters included (i) 
sensitivity; (ii) precision (intra- and inter-assay); (iii) recovery (selectivity); (iv) linearity of dilution; 
(v) parallelism and (vi) inter-laboratory precision. The data showed good assay sensitivity and 
precision. Inter-laboratory precision was sub-optimal. Reasons for this have yet to be elucidated but 
may include pre-analytical methodological variation or differing levels of operator experience with 
the assay and / or SOPs. Over-all this assay is suitable for the quantification of NfL in human CSF but 
sources of inter-laboratory variation require further investigation, and need to be controlled for, before 
subsequent multi-centred validations of this assay be pursued and the true benefit of standardised 
practice in multi-site settings established.        
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Introduction 
Fluid biomarkers, cerebrospinal fluid (CSF) biomarkers in particular, are increasingly being 
used to support the clinical diagnosis of Alzheimer’s disease (AD) and their utility to support the 
differential diagnosis of other forms of dementia and neurodegeneration has also been 
acknowledged
1,2,3,4,5,6
.  
Neurofilament light (NfL) is one such candidate CSF biomarker. It comprises one of 4 
cytoskeletal subunits of neuronal intermediate filaments and serves to maintain the shape of nerve 
cells and facilitate radial axonal growth hence maintaining neuronal conduction velocity
7,8
. Increased 
concentrations of NfL in the CSF are thought to reflect nerve cell damage or death
9
 and have been 
shown to correlate with the severity of head trauma
10
, to reflect the degree of degeneration in certain 
dementia subtypes
11
 as well as increased rates of cognitive decline and disease progression in 
Alzheimer’s patients12.  Furthermore, NfL has demonstrated utility as a clinical indicator of disease 
severity, progression and prognosis as well as a support for patient stratification or a proxy measure of 
therapeutic efficacy in other neurodegenerative conditions such as multiple sclerosis (MS)
13
, 
amyotrophic lateral sclerosis (ALS)
14
 and Parkinson’s disease (PD)11,15-20.  
CSF neurofilaments, similar to other CSF biomarkers, can be measured for clinical or 
research purposes using routine analytical platforms such as enzyme-linked immunosorbent assays 
(ELISAs)
 18,20
.  However, for medical practitioners and researchers to recognise and accept the use of 
neurofilaments, and other neurodegenerative CSF biomarkers into routine diagnostic processes or 
clinical and research programmes, the reliability and reproducibility of their quantification needs to be 
established
21-23
. This is only possible by stringently validating the performance parameters of the 
various analytical platforms prior to using them for routine clinical or research purposes. To date 
attempts at investigating the performance of assays for amyloid and neurodegenerative biomarkers of 
AD have proven to be problematic with unacceptable levels of inter-laboratory variation being 
reported
24,25
. More recently, a multicentre NfL ELISA assay validation experiment, which examined 
whether parameters such as pipette calibration, duration of colorimetric development or delay in 
analysis could contribute to the observed high levels of inter-laboratory variation reported that 
disparity in the accuracy of standard preparation, contributed most significantly to the observed large 
inter-laboratory coefficient of variation (59%) in that particular experiment
26
.  
The purpose of the present work was to implement a standardised immunoassay validation 
protocol across multiple international research centres and in doing so determine the suitability of an 
established ELISA assay to quantify CSF NfL concentrations to facilitate implementation in clinical 
practise.  Novel biomarker validation experiments comprise a subtask of the BIOMARKAPD project, 
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a Joint Programme Neurodegenerative Disease (JPND) initiative, which seeks to optimise the 
performance of fluid biomarkers for the diagnosis of AD and PD. The standard operating procedures 
(SOPs) used in these experiments were devised specifically for the BIOMARKAPD novel biomarker 
assay validation project. They were designed for the partial validation of commercially available 
novel biomarker assays. Their purpose was to allow for easy implementation of standardised assay 
validation protocols and appraisal of the performance of the assay without having to assess the kits 
performance in relation to robustness i.e. its ability to perform despite slight methodological 
variation
27
. 
Methods 
Study design 
The validation experiments were performed according to ISO/IEC 17025, ISO 5725-2, ISO 5725-4 
criteria and the validation protocol was devised with reference to several supporting guidance 
publications
28-35
. Six laboratories located in Sweden, Denmark, Germany, Norway, Finland and 
Ireland took part in the study. The laboratories, with varying levels of familiarity with the assay 
ranging from first time to experienced users, received five UmanDiagnostics NfL ELISA kits (cat. 
#10-7001, Umea, Sweden) and 20 clinical CSF samples of known NfL concentration for inter-
laboratory accuracy analysis. For all other validation experiments participating laboratories used 
locally obtained CSF samples. Each laboratory was provided with identical immunoassay validation 
protocol and data reporting templates. All laboratories were required to assess the UmanDiagnostics 
NfL ELISA kits performance with respect to six validation parameters which included an assessment 
of the kit’s (i) sensitivity, (ii) precision (inter- and intra- assay), (iii) recovery (selectivity), (iv) 
linearity of dilution, (v) parallelism and (vi) inter-laboratory accuracy. Acceptable performance for 
each of the parameters measured was set at +/- 15% of the optimum performance (100%) or a 
coefficient of variation (%CV) below 15%
36
.  
ELISA 
The NfL ELISA kits were used for quantitative determination of NfL in human CSF samples.  
ELISAs were performed according to the manufacturer’s instructions and as described before18,26.  
In brief, standards (lyophilised bovine NfL spinal cord concentrate - TBC) were re-suspended in 
sample diluent to give a top concentration of 10,000pg/mL. The top standard was vortexed briefly and 
kept at room temperature (RT). The remaining standards were prepared from serial dilutions of the 
top standard and are summarised in Table 1. Initially plates were washed (x3) with wash buffer 
(300μL), they were then flipped over and wash buffer residues removed by tapping the plate against 
blotting paper. Next 100μL of standard or sample were added to each well according to the 
experimental templates and incubated for 1hr at RT (20-25
0
C) with agitation (800rpm). Subsequently, 
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plates were washed (x3) as described above and 100μL of freshly diluted tracer (biotin labelled 
antiNfL mAb) was added to each well and incubated for 45min at RT (20-25
0
C) with agitation 
(800rpm). Again, plates were washed (x3) and 100μL of newly diluted conjugate (streptavidin-HRP) 
was added to each well and incubated for 30min at RT (20-25
0
C) with agitation (800rpm). Next, 
plates were washed (x3) and 100μL of TMB was added to each well and incubated for 15min at RT 
(20-25
0C) with agitation (800rpm). Finally, 50μL of stop solution was added to each well and the 
absorbance read at 450 nm.  
 
Sensitivity 
The sensitivity of the assay was determined by running 16 blank samples (sample diluents). Mean and 
standard deviations (SDs) of the blanks were calculated and the lower limit of detection (LLOD) was 
calculated based on a signal of 10 SDs above the mean of the blanks. 
Precision 
To assess the precision of the assay, five quality control (QC) samples with pre-defined low and high 
NfL content within the linear range of the standard curve were collected by each laboratory. The 
samples were divided into 24 aliquots and stored at -80
o
C until needed. For the intra-assay precision 
12 replicates of each QC sample were run on day one. For the inter-assay precision three replicates of 
the samples were run on days two through five. The mean, SDs and %CV were calculated for 
repeatability (inter-assay) and intermediate precision (intra-assay).  
Recovery 
Recovery (selectivity) was assessed over two days. Five CSF samples of known low NfL content 
were used in these experiments. On both days the samples (three samples day one; two samples day 
two) were diluted 1:1 as per assay requirements and divided into four aliquots. Three of the aliquots 
were spiked with calibrator stock solution to low, medium and high NfL concentrations on the linear 
range of the standard curve. Samples were spiked with 5% volume to 95% volume of the diluted 
sample. The fourth aliquot was spiked with an equal volume of the sample diluent (neat sample).  
Recovery was calculated according to the following formula:  
%Recovery = ((Measured concentrationspiked samples – Measured concentrationneat samples) / 
Theoretical concentrationspiked) x 100.   
Linearity of dilution 
To assess the linearity of dilution three pre-selected undiluted CSF samples with known high 
concentrations of NfL were selected and spiked with calibrator stock solution to a concentration 
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beyond the upper limit of detection (ULOD) of the assay (10µg/mL). Serial dilutions of each spiked 
sample were carried out until the concentration was below the lower limit of detection (LLOD).  
Linearity of dilution was calculated according to the following formula:  
%Linearity = (Observed concentration x Dilution factor / (Previous observed concentration x 
Dilution factor in the dilution series)) x 100.  
Parallelism 
Parallelism was assessed by investigating whether an equivalent relationship exists between the 
detection of the native NfL content in the CSF samples and the calibrator protein in assay diluent. For 
this purpose four CSF samples with known high NfL concentrations were chosen and a fifth sample 
of sample diluent was prepared by spiking the diluent with calibrator stock solution to a concentration 
equivalent to one of the native samples. A minimum of three and maximum of five serial dilutions 
were then performed on the samples to reach a NfL concentration below the lower limit of 
quantification. A parallel relationship was defined by comparing the slope of the calibrator to the 
mean slopes of the four CSF samples at various dilution factors. Parallelism was calculated by taking 
the mean signal of the four CSF samples at each dilution factor and comparing it to the signal of the 
spiked sample diluent. The % parallelism was calculated according the following formula:   
%Parallelism = (Slope(a)Samples / Slope(a)Calibrator) x 100.  
Inter-laboratory accuracy samples 
Twenty de-identified CSF samples (3-5mL volumes) of pre-determined NfL concentration (190-
25,000 pg/mL) were provided by the Clinical Neurochemistry Laboratory, Sahlgrenska University 
Hospital, Mölndal, Sweden. The study from which the CSF samples were collected was approved by 
the local ethics committee at the University of Gothenburg.  CSF samples were collected through 
lumbar puncture in the L3/L4 or L4/L5 interspace into polypropylene tubes, centrifuged (2200 x g; 
10min; 20
o
C) and stored in polypropylene tubes at -80
o
C pending biochemical analysis. Following 
shipment to Dublin, Ireland (the project co-ordinating site) the samples were thawed and further 
aliquoted (250 μL) into 0.5mL tubes and redistributed among the participating laboratories. Inter-
laboratory accuracy was calculated by comparing the %CV of each of the 20 CSF sample measured 
across the six participating laboratories. 
Data analysis 
All data analysis was performed by the project coordinating site to ensure uniformity of results. 
Standardised project reporting templates were used to calculate the results were applicable. Data was 
analysed using Excel (Microsoft, Version 2010) and GraphPad (GraphPad Software Inc, Version 5.0, 
La Jolla, CA, USA) was used to create figures.  
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Results 
Sensitivity 
The mean LLOD reported by the six laboratories based on the 16 blank samples was 57.5 pg/ml and 
ranged from 23.3 pg/ml to 100 pg/ml (Table 2). The manufacturer’s reported LLOD is 32 pg/ml.  
Precision 
The average intra-assay CV based on the calculated NfL concentrations was 3.7% and ranged from 
1.7 to 7.1% (Figure 1a). The average inter-assay CV for the low NfL content samples was 13.2% 
(range 4.0 to 21.1%), for medium NfL content samples 12.4% (5.9 to 18.1%) and for the high NfL 
content samples 15% (9.8 to 21.2%) resulting in an average inter-assay CV of 13.5% for all samples 
(Figure 1b). 
Recovery (selectivity) 
The reported recovery percentages were, in most cases outside the pre-defined range of 85-115%. 
Only samples spiked to medium NfL content in Lab #1 and #2 and to high NfL content in Lab #2 
were within the pre-defined range (Table 3).  
Linearity of dilution 
The data showed that 30% of all dilutions did not fall within the pre-defined range of 85%-115% 
(Figure 2).  
Parallelism 
Two of the 6 participating laboratories (Lab #2 and #5) reported parallelism within the pre-defined 
range of 85-115% (Figure 3).  
Inter-laboratory precision 
The inter-laboratory accuracy of the measurements of NfL concentrations was assessed with 20 CSF 
patient samples distributed between six laboratories. The inter-laboratory CV for all samples was 27% 
(range 16% to 32%) and was outside the pre-defined level of 15% (Figure 4). The data showed that 
samples with the highest NfL content had the lowest %CV (Figure 4a).  
The differences in the standard curve OD values reported by the centres do not explain the high inter-
laboratory %CV of the samples (Figure 4b). For instance, difference in the OD values of the standard 
curve between Lab #3 and Lab#5 is on average 29% but the average difference in the calculated NfL 
concentrations is 14%. However, in another example, the difference in the OD values of the standard 
curve between Lab #1 and Lab #5 was 7% but the average difference of calculated NfL 
concentrations was 25%. 
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In order to elucidate possible sources of variation which might account for the high inter-laboratory 
%CV the participating laboratories were asked to complete a questionnaire (adapted from Petzold et 
al., 2010) regarding the sample and kit handling conditions during the series of experiments.  
In brief, variation was found in the sample storage conditions and time taken to incubate the standards 
and samples following reconstitution of the calibrator (15-60min), minor variations in the time 
allowed for the colour reaction and whether plates were protected from sunlight were also observed. 
No difference was observed with respect to ELISA kit storage conditions, the temperatures at which 
the assays were executed and plate agitation details. In two of six cases pipettes were calibrated prior 
to the validation experiments. The 20 inter-laboratory patient CSF samples used by 5 of the 6 
laboratories underwent two shipments on dry ice with the exception of those used by the co-ordinating 
site. The assay data was calculated using the 4 parameter logistic (4PL) nonlinear regression model by 
all six laboratories (Table 4). 
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Discussion 
The data showed that the assay has good sensitivity with an average LLOD reported by the 
participating laboratories of 57.5 pg/ml. Assay precision, as assessed by measuring inter- and intra-
assay CV was good at 13.2% and 3.7% respectively. Importantly however, it must be noted that that 
maximal spiking using assay calibrator, particularly in the recovery and linearity of dilution 
experiments was not, in most cases, achieved. This is due to the fact that the lyophilised calibrator is 
pre-diluted 1:1 by the manufacturer to allow for the 1:1 dilution of the samples in accordance with the 
NfL ELISA assay protocol thus, once re-suspended in diluent, the true concentration of the calibrator 
is in reality half of what is assumed. This pre-dilution of the calibrator was accounted for during 
calculations by the data coordinating site so that the data reflected ‘true’ calibrator concentrations.  
Recovery (selectivity) 
Recovery was assessed by measuring non-native NfL in the presence of endogenous CSF matrix, 
selectivity of the assay in the six laboratories was for the most part outside the pre-defined range of 
85-115%. Usually poor recovery points to interference in sample measurement by components in the 
matrix, such as blood contamination, which may affect antibody binding
37
 and is usually resolved by 
the addition of additional assay diluent to samples
27
. However, in this instance confounding elements 
such as the blood contamination status of the samples was unknown, this fact, in combination with the 
calibrator concentration miscalculation means that the recovery data must be interpreted with caution. 
However, if the assay were to display poor selectivity the observed values would tend to deviate in 
one direction, that is, either positive or negative. However, the results reported in this experiment 
showed that the data seemed to deviate in both directions suggesting that factors, other than those 
traditionally thought to affect selectivity, contributed to the poor recovery. Thus in the absence of a 
matrix effect it must be considered that recovery may have been hampered by the use of non-native 
(bovine) NfL calibrator protein to spike the CSF samples which might behave differently than native 
(human) NfL protein in the CSF
37
.  
Linearity of dilution 
It is important to be able to demonstrate that if the concentration of a protein of interest is above the 
ULOQ of an assay that it can be diluted, without affecting accuracy of measurement, to a 
concentration within the working range of the assay
34
.  Linearity of dilution was suboptimal in these 
experiments as 30% of dilutions were outside the pre-defined acceptance range. Similar to the 
recovery experiments poor linearity of dilution can imply that the sample matrix and assay diluent 
affect analyte detection differently
27
 but, again, it is difficult to assess the validity of these results due 
to the assumed starting concentration of the calibrator being incorrect. Consequently only two- or 
three-fold dilutions of samples were made in these experiments before the LLOD was reached when 
normally four or five-fold dilutions would be compared. The ‘hook effect’ can also be discounted as 
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an influencing factor in this experiment. The ‘hook effect’ is observed when the analyte in question is 
in very high concentrations beyond the theoretical upper limit of detection of the assay and can result 
in artificially low concentrations of analyte being reported
38
. However this phenomenon was not 
observed in these experiments as, again, the working concentration of the calibrator used for spiking 
was significantly lower than originally assumed.   
Parallelism 
We examined parallelism comparing standard bovine NfL in assay diluent and endogenous NfL in 
CSF. Antibody affinity was investigated by comparing the slopes for the native NfL in CSF versus the 
calibrator protein in assay diluent. As two of six centres observed a parallel relationship between their 
samples and the calibrator sample we cannot conclude that the antibodies used in the assay have poor 
affinity.  
A failure to observe parallelism could point to poor robustness in this particular experiment; however 
this can only be established by a more in-depth systematic examination of critical factors such as pre-
analytical variables pertinent to this validation parameter
28
. Alternatively, failure to observe 
parallelism, and indeed some of the other validation parameters, could be in part due to some of the 
less practiced operators experiencing difficulty with interpretation or complexity of the plate plans 
and SOPs. It has been argued that as NfL has the tendency to re-aggregate following suspension
39-42 
that delays in sample and standard incubation could account for the failure to satisfactorily measure 
NfL in many experiments
26
. The data show that between 15 and 60 minutes were taken, from the time 
standards were reconstituted, to incubate the standards and samples on the ELISA plates. The 
observed delay could be in part due to a lack of operator familiarity with the assay protocol or project 
SOPs. On foot of this observation we recommend that for validation experiments the operator use 
both vials of standard stock solution supplied in the kits to prepare the standard curve and spike 
samples as promptly as practicable. By using both vials during the course of the validation time to 
incubation of standards and samples would be significantly cut, diminishing the possibility of NfL 
protein aggregation and/or degradation contributing to variation in the performance of this assay 
across sites. Furthermore, future validation projects could be further optimised by adopting alternative 
assay validation SOPs such as those recently published by BIOMARKAPD
43
 which are designed to 
allow for the inexperienced operator.  
Inter-laboratory precision 
The inter-laboratory CV at 27% is poor but cannot, as in other assay validation experiments be 
attributed to lot to lot variation in the kits
44
 as all centres taking part worked with kits from the same 
lot. Nonetheless, despite the variation the data do point to the positive effects of implementation of a 
standardised protocol in that no one laboratory reported consistently high or low values and 
discrepancies seem to be spread out among the laboratories. In support of the positive effect of 
implementation of validation protocols a previous multi-centre study, albeit with greater numbers of 
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participating laboratories, which did not use standardised protocols in the validation of the 
UmanDiagnostics NfL ELISA reported a significantly higher inter-laboratory precision CV of 59%
26
.  
In agreement with our observations, Petzold and colleagues also observed variations in the 
concentration of standards and their associated optical densities (OD)
26
. They noted that non-
systematic error due to variations in the preparation of standards could be responsible for up to two- 
fold differences in sample concentration, and identified differences in the accuracy and types of 
pipettes used to make the standards and dispense samples as possible sources of variation. Our own 
data indicates that four of the six centres reported not calibrating their pipettes prior to the validation 
experiments and declared using different pipettes for the preparation of the assay standards as to those 
used for pipetting samples. However, given the available data we are unable to definitively identify a 
reason for the inter-laboratory variation and further studies examining pre-analytical variation within 
the context of using standardised SOPs in a multi-centre context should be conducted. 
Limitations and recommendations 
A regularised approach to assay performance is required to ensure the validity of intra- and inter-
laboratory data and the performance of multi-site clinical or research studies. This will ultimately lead 
to the optimisation of novel biomarkers, increase clinician confidence in the veracity of CSF 
biomarker results, resulting in their increased incorporation into routine clinical research and 
diagnostic processes. The data tentatively show that a standardised SOP can lend itself to greater 
control of the evaluation and reporting of the performance of immunochemical assays but due to the 
inconclusive results in some of the parameters examined in these experiments the outcome of this 
validation should be interpreted with caution.  As yet too many factors, including pre-analytical 
procedures and the effect of delays in the execution of some of the experiments remain uncontrolled 
for in order to assess the true effect of standardised SOPs in a multi-centre study. In addition 
highlighting the dilution status of the lyophilised calibrator and use of both kit calibrators for any 
spiking experiments would greatly enhance the success of subsequent validations of this assay. 
Nonetheless given the data we conclude that the UmanDiagnostics ELISA kit for detection of human 
NfL is suitable for routine NfL quantification. However, we caution against comparing patient data 
sourced from different centres until the reasons for the high inter-laboratory CV are identified. We 
also recommend that going forward SOPs which minimise procedural complexity and allow for 
operator naïveté should be considered for future multi-centre validation studies. 
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Figures 
 
Standard Preparation: 
Tube # Sample Diluent Standard from 
tube # 
Concentration 
(pg/mL) 
1 Per vial label 10000 
2 300μL 300μL (1) 5000 
3 300μL 300μL (2) 2500 
4 360μL 240μL (3) 1000 
5 300μL 300μL (4) 500 
6 240μL 60μL (5) 100 
7 300μL 0μL 0 
 
Table 1: Standard dilutions per manufacturer’s instruction 
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 Lab #1 Lab #2 Lab #3 Lab #4 Lab #5 Lab #6 Mean 
LLOD (pg/ml) 40.8 23.3 56.4 100.0 75.0 49.6 57.5 
 
Table 2. Lower limit of detection (LLOD). The mean LLOD reported by six laboratories was 57.5 
pg/ml and ranged from 23.3 pg/ml to 100 pg/ml.  
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Figure 1. The assay had low inter- and intra- assay CV%. a) The average intra-assay CV% based 
on calculated NfL concentrations was 3.7% (range 1.7 to 7.1%). (b) The average inter-assay CV% for 
the low NfL content samples was 13.2% (range 4.0 to 21.1%), for medium NfL content samples 
12.4% (5.9 to 18.1%) and for the high NfL content samples the average was 15% (9.8 to 21.2%) 
giving the average inter-assay CV for all samples among all the labs of 13.5%.       
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 Lab #1 Lab #2 Lab #4 Lab #5 Lab #6 
Mean recovery 
S
p
ik
e 
low 207% 125% 129% -96% 122% 
medium 115% 104% 133% 10% 128% 
high 132% 95% 139% 42% 128% 
Recovery range (%) 
S
p
ik
e low 197-222 109-140 118-141 -454 - 129 93-109 
medium 58-157 95-116 118-148 -118 - 92 118-146 
high 119-152 93-100 125-151 -35 - 85 117-139 
 
Table 3. The NfL Elisa assay used in the study had low selectivity and specificity. The selectivity 
of the assay was assessed using recovery experiments with three CSF samples with known low NfL 
content and spiked to low, medium and high NfL concentration with calibrator. The reported recovery 
percentages were, in most cases, either below or above the pre-defined range of 85-115%.  
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Figure 2. Linearity of dilution. The data showed that dilution of linearity was largely within the pre-
defined range of 85%-115%. The graph shows % linearity for three samples per lab. The continuous 
line indicates 100% linearity and two dotted lines indicate lower (85%) and upper (115%) pre-defined 
ranges respectively. The “hook effect” was not observed in any of the laboratories (data not shown). 
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 Lab #1 Lab #2 Lab #3 Lab #4 Lab #5 Lab #6 
Parallelism  144% 111% 174% 61% 109% 141% 
 
Figure 3. Affinity was investigated looking at parallelism between the sample diluent spiked 
with NfL calibrator and four neat CSF samples. (a) Two out of five laboratories reported 
parallelism within the pre-defined range of 85 – 115% (Lab #2 and Lab #5). The remaining four 
laboratories reported parallelism outside the pre-defined range.  
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 Lab#2 Lab#3 Lab#4 Lab#5 Lab#6 
Lab#1 51%/24% 31%/32% 24%/47% 7%/25% 24%/22% 
Lab#2 - 30%/15% 38%/36% 50%/9% 36%/20% 
Lab#3 - - 17%/26% 29%/14% 15%/33% 
Lab#4 - - - 21%/32% 13%/48% 
Lab#5 - - - - 23%/23% 
 
 
Figure 4. Profile of 20 patient CSF samples analysed in six laboratories across Europe. (a) 
Average CV for each sample analysed in six laboratories plotted against sample concentration (µg/ml) 
shows that the samples with the highest NfL content had the lowest CV. (b) Differences between OD 
values of the standard curve do not explain the high inter-laboratory CV of the samples. The table 
shows mean per cent difference of OD values of the standard curve and the mean per cent difference 
of the calculated NfL concentrations.  
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Parameters 
Lab 
#1 
Lab 
#2 
Lab 
#3 
Lab 
#4 
Lab 
#5 
Lab 
#6 
Sample storage prior to analysis  (
o
C) -80 -80 -80, 4 -80 -80 -80 
ELISA kit storage prior to analysis (
o
C) 4 4 4 4 2-8 2-9 
Temperature (
o
C) at which ELISA was 
performed 
21-22 21-22 22-24 20-24 21-22 20-24 
Pipettes calibrated prior to experiment No Yes Yes No No No 
100-200 µl pipette tips used for loading 
samples 
Yes Yes Yes Yes No Yes 
Time from standard preparation to the 
start of incubation on the plate (minutes) 
20-60 < 60 < 60 < 30 15 15 
Different pipettes used for preparing  
   Standards 
Yes Yes Yes No No Yes 
Plate agitation at which incubations were  
 performed (rpm) 
800 800 800 800 800 800 
Time of colour reaction (minutes) 15 20 15 15 15 15 
Plate protected from light during colour  
Reaction 
Yes No Yes No Yes Yes 
No. of freeze/thaw cycles of samples 
before shipment 
2 2 2 2 2 2 
No. of shipments before samples assayed 1 2 2 2 2 2 
Sample condition on arrival Frozen Frozen Frozen Frozen Frozen Frozen 
Curve fitting model used for data analysis 4PL 4PL 4PL 4PL 4PL 4PL 
 
Table 4. Sample processing and assay handling parameters. (Adapted from Petzold et al., 2010) 
 
 
 
 
 
 
